BioMark's Liquid Biopsy Technology Offers Promise for NEN Diagnosis Vancouver, British Columbia--(Newsfile Corp. - September 24, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is excited to announce that its latest work, has been published in Cancers, titled "Metabolic Profiling of Pulmonary Neuroendocrine Neoplasms." This paper sheds light on the metabolic alterations that define pulmonary neuroendocrine neoplasms (NENs), focusing on identifying specific metabolomic biomarkers for early diagnosis and monitoring.
ALLSTON, Mass. , Aug. 8, 2024 /PRNewswire/ -- On September 30, 2024, New England Realty Associates Limited Partnership (NYSE MKT: NEN) will make its quarterly distribution to its Class A Limited Partners and holders of Depositary Receipts of record as of September 13, 2024.